Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Holtzman

Showing results (631-640 of 743) with videos related to

Pageof 75
Sort By:
JAMA Neurology|July 28, 2024
Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive ImpairmentShorena Janelidze, Nicolas R Barthélemy, Gemma Salvadó, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 15, 2018
NIA-AA Research Framework: Toward a biological definition of Alzheimer's diseaseClifford R Jack, David A Bennett, Kaj Blennow, et al.
Nature Medicine|March 31, 2025
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's diseaseKanta Horie, Gemma Salvadó, Rama K Koppisetti, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2017
Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer's diseaseRobert J Andrew, Celia G Fernandez, Molly Stanley, et al.
Plos One|January 26, 2011
Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's diseaseRichard J Perrin, Rebecca Craig-Schapiro, James P Malone, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 20, 2024
APOE2 gene therapy reduces amyloid deposition and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer diseaseRosemary J Jackson, Megan S Keiser, Jonah C Meltzer, et al.
Medrxiv : the Preprint Server for Health Sciences|July 28, 2023
Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer's diseaseGemma Salvadó, Kanta Horie, Nicolas R Barthélemy, et al.
JAMA Neurology|July 7, 2015
Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle AgeCourtney L Sutphen, Mateusz S Jasielec, Aarti R Shah, et al.
BMC Neurology|November 12, 2016
Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40Yuetiva Deming, Kathleen Black, David Carrell, et al.
Neuron|November 23, 2023
Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonistAlexandra Litvinchuk, Jung H Suh, Jing L Guo, et al.
Pageof 75

Showing results (631-640 of 743) with videos related to

Sort By:
Pageof 75
JAMA Neurology|July 28, 2024
Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive ImpairmentShorena Janelidze, Nicolas R Barthélemy, Gemma Salvadó, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 15, 2018
NIA-AA Research Framework: Toward a biological definition of Alzheimer's diseaseClifford R Jack, David A Bennett, Kaj Blennow, et al.
Nature Medicine|March 31, 2025
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's diseaseKanta Horie, Gemma Salvadó, Rama K Koppisetti, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2017
Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer's diseaseRobert J Andrew, Celia G Fernandez, Molly Stanley, et al.
Plos One|January 26, 2011
Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's diseaseRichard J Perrin, Rebecca Craig-Schapiro, James P Malone, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 20, 2024
APOE2 gene therapy reduces amyloid deposition and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer diseaseRosemary J Jackson, Megan S Keiser, Jonah C Meltzer, et al.
Medrxiv : the Preprint Server for Health Sciences|July 28, 2023
Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer's diseaseGemma Salvadó, Kanta Horie, Nicolas R Barthélemy, et al.
JAMA Neurology|July 7, 2015
Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle AgeCourtney L Sutphen, Mateusz S Jasielec, Aarti R Shah, et al.
BMC Neurology|November 12, 2016
Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40Yuetiva Deming, Kathleen Black, David Carrell, et al.
Neuron|November 23, 2023
Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonistAlexandra Litvinchuk, Jung H Suh, Jing L Guo, et al.
Pageof 75